



## Article

# Induction of Broadly Cross-Reactive Antibodies by Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like Particles

Xinyue Chang<sup>1,2,†</sup>, Xuelan Liu<sup>3,†</sup>, Mona O. Mohsen<sup>1,2,4</sup>, Andris Zeltins<sup>5</sup>, Byron Martina<sup>6</sup>, Monique Vogel<sup>1,2</sup>   
and Martin F. Bachmann<sup>1,2,3,7,\*</sup> 

<sup>1</sup> Department of Rheumatology and Immunology, University Hospital Bern, 3010 Bern, Switzerland; xinyue.chang@dbmr.unibe.ch (X.C.); mona.mohsen@dbmr.unibe.ch (M.O.M.); monique.vogel@dbmr.unibe.ch (M.V.)

<sup>2</sup> Department of BioMedical Research, University of Bern, 3012 Bern, Switzerland

<sup>3</sup> International Immunology Centre, Anhui Agricultural University, Hefei 230036, China; xuelan.liu@dbmr.unibe.ch

<sup>4</sup> Saiba GmbH, 8088 Pfäffikon, Switzerland

<sup>5</sup> Latvian Biomedical Research & Study Center, Ratsupites 1, LV1067 Riga, Latvia; anze@biomed.lu.lv

<sup>6</sup> Artemis Bio-Support, 2629 Delft, The Netherlands; b.martina@artemis-biosupport.com

<sup>7</sup> Jenner Institute, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7BN, UK

\* Correspondence: martin.bachmann@dbmr.unibe.ch

† These authors contributed equally to this work.



**Citation:** Chang, X.; Liu, X.; Mohsen, M.O.; Zeltins, A.; Martina, B.; Vogel, M.; Bachmann, M.F. Induction of Broadly Cross-Reactive Antibodies by Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like Particles. *Vaccines* **2022**, *10*, 307. <https://doi.org/10.3390/vaccines10020307>

Academic Editors: Esther Blanco and Juan Bárcena

Received: 27 December 2021

Accepted: 11 February 2022

Published: 16 February 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** The impact of the COVID-19 pandemic has been reduced since the application of vaccination programs, mostly shown in the reduction of hospitalized patients. However, the emerging variants, in particular Omicron, have caused a steep increase in the number of infections; this increase is, nevertheless, not matched by an increase in hospitalization. Therefore, a vaccine that induces cross-reactive antibodies against most or all variants is a potential solution for the issue of emerging new variants. Here, we present a vaccine candidate which displays receptor-binding domain (RBD) of SARS-CoV-2 on virus-like particles (VLP) that, in mice, not only induce strong antibody responses against RBD but also bind RBDs from other variants of concern (VOCs). The antibodies induced by wild-type (wt) RBD displayed on immunologically optimized Cucumber mosaic virus incorporated tetanus toxin (CuMV<sub>TT</sub>) VLPs bind to wt as well as RBDs of VOCs with high avidities, indicating induction of strongly cross-reactive IgG antibodies. Interestingly, similar cross-reactive IgA antibodies were induced in immunized mice. Furthermore, these cross-reactive antibodies demonstrated efficacy in neutralizing wt (Wuhan) as well as SARS-CoV-2 VOCs (Beta, Delta, and Gamma). In summary, RBDs displayed on VLPs are capable of inducing protective cross-reactive IgG and IgA antibodies in mice, indicating that it may be possible to cover emerging VOCs with a single vaccine based on wt RBD.

**Keywords:** COVID-19; vaccine; virus-like particle; CuMV<sub>TT</sub>

## 1. Introduction

The COVID-19 pandemic recently has been more dominated by variants of concern (VOCs) that have emerged in different countries around the globe [1–5]. Mutations in the RBDs of these VOCs have been characterized in detail, and it was found that some mutations (e.g., E484K present in B.1.351 and P.1 variants) reduce recognition by antibodies induced by the wt SARS-CoV-2 strain [6–8], while other mutations (N501Y in B.1.1.7, B.1.351 and P.1 variants or L452R and E484Q in B.1.617.1 variant) primarily enhance affinity for the ACE2 receptor (Table 1) [9,10] likely being responsible for the enhanced infectivity of the latter strains. Both types of mutations cause reduced neutralization of VOCs by wt

SARS-CoV-2 induced convalescent sera, either due to reduced recognition of the RBD or impaired competition of RBD with its receptor ACE2 [9].

**Table 1.** Mutations of VOCs compared with wild type in RBD [11] and corresponding affinity to ACE2 [9,10].

Strain	First Reported Country	Mutations in RBD	Affinity to ACE2
Wild type	Wuhan	K417, L452, T478, E484, N501	$20.5 \times 10^{-9}$ M
Alpha (B.1.1.7)	United Kingdom	N501Y	$6.2 \times 10^{-9}$ M
Beta (B.1.351)	South Africa	K417N, E484K, N501Y	$10.3 \times 10^{-9}$ M
Gamma (P.1)	Brazil	K417T, E484K, N501Y	/
Kappa (B.1.617.1)	India	L452R, E484Q	$4.6 \times 10^{-9}$ M

While recognition by convalescent sera of some RBDs of VOC, e.g., E484K, is essentially abolished, vaccine-induced antibodies seem to be more cross-reactive in the fact that they recognize the newly emerged RBDs with enhanced avidity compared to convalescent sera and show some cross-neutralization both in humans [6] and mice [12]. While attempts have been made to modify mRNA vaccines to adjust for the new VOCs, success was rather limited, and neutralization of VOCs induced by the adjusted vaccine was not better than the values achieved with the wt mRNA vaccine [13]. Hence, a simpler strategy may be to search for vaccine candidates that induce neutralizing antibodies against all VOCs.

CuMV<sub>TT</sub> is a previously described virus-like particle (VLP) derived from the cucumber mosaic plant virus, which has been immunologically optimized by incorporating a universal T helper cell epitope derived from tetanus toxin, expected to facilitate induction of T helper cell-dependent IgG responses [14,15]. In addition, CuMV<sub>TT</sub> is expressed in *E. coli* and spontaneously packages bacterial RNA, which serves as a TLR7/8 ligand and is optimal for enhancing IgG and IgA responses [16]. For example, CuMV<sub>TT</sub>-Ara h 1 was demonstrated to effectively treat peanut allergy in mice [17]. Another example of CuMV<sub>TT</sub> as an excellent vaccine delivery vehicle was against MERS coronavirus, which was potent to induce high titers of RBD- and spike protein-specific IgG antibodies, which could neutralize virus in vitro [18].

Here we demonstrate that wt RBD displayed on CuMV<sub>TT</sub> may be a candidate for inducing polyvalent protective immunity, as it induces antibodies in mice that broadly recognize and neutralize all VOCs tested.

## 2. Materials and Methods

### 2.1. Animal Ethics

All studies involving animals were approved by the Cantonal Veterinary Office in Bern, Switzerland. All animal experiments were performed according to regulations and guidelines of the Cantonal Veterinary Office Bern, Switzerland (license BE70/18). There is no human material involved in this study.

### 2.2. RBD Proteins Expression and Purification

The production and purification of RBD proteins were described previously [19]. Briefly, The RBD variants (RBD<sub>wt</sub>, RBD<sub>trip</sub>, RBD<sub>417</sub>, RBD<sub>484</sub>, RBD<sub>501</sub>, and RBD<sub>dm</sub>) were expressed in mammalian Expi293F cells (Gibco, ThermoFisher Scientific, Waltham, MA, USA). Plasmids containing genes encoding wild type and mutated RBD proteins (residues Arg319-Phe541) with a 6-His tag at C-terminus were synthesized from Twist Bioscience, San Francisco, USA and amplified in bacterial XL-1 Blue competent cells. Then Expi293F cells ( $3 \times 10^6$  cells/mL) were transfected with expression plasmids by using ExpiFectamine 293 transfection kit (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) according to the manual. Seven days after transfection, cell culture supernatants containing RBDs were collected by centrifugation and filtration. RBDs were purified with His-Trap HP column

(GE Healthcare, Wauwatosa, WI, USA) and dialyzed in PBS buffer. Purified RBDs were analyzed in SDS-PAGE gel.

### 2.3. Displaying RBDs on VLP Surface

RBD<sub>wt</sub> protein was covalently linked to CuMV<sub>TT</sub> VLPs with the cross-linker Succinimidyl 6-(beta-maleimidopropionamido) hexanoate (SMPH) (Thermo Fisher Scientific, Waltham, MA, USA), as described previously [19]. The linker firstly was incubated with CuMV<sub>TT</sub> for 30 min at room temperature, and meanwhile, RBD<sub>wt</sub> was reduced by mild reducing agent Tris-(2-Carboxyethyl) phosphine (TCEP) (Invitrogen, Waltham, MA, USA). The molar ratio of SMPH to CuMV<sub>TT</sub> was optimized to 5:1, and RBD<sub>wt</sub> to CuMV<sub>TT</sub> was 1:1. Then the CuMV<sub>TT</sub> was mixed with reduced RBD<sub>wt</sub> protein and incubated for 3 h with 400 rpm shaking. Subsequently, the coupling was analyzed in SDS-PAGE gel, and coupling efficiency was calculated by densitometry (20–30% efficiency). In addition, the conjugated CuMV<sub>TT</sub>-RBD<sub>wt</sub> products were characterized in agarose gel to determine the content of ssRNA.

### 2.4. Transmission Electron Microscope (TEM)

The integrity of the CuMV<sub>TT</sub>-RBD<sub>wt</sub> VLP sample was assessed by TEM, and 5 µL of VLP solutions were dropped on grids for 1 min and rinsed by dipping into the water 3 times. The grids were then stained with 2% uranyl acetate solution (Electron Microscopy Science, Hatfield, PA, USA) for 45 s. The excess solution was gently removed by filter paper. Images were captured with a digital camera (Veleta, Olympus, Münster, Germany) under a transmission electron microscope (Tecna Spirit, FEI, Hillsboro, OR, USA) at 80 kV.

### 2.5. Immunization of Mice

BALB/cOlaHsd mice (female) were purchased from Envigo (Horst, The Netherlands) at the age of 7 weeks. Mice were kept in a specific pathogen-free (SPF) facility in the Department of BioMedical Research (DBMR) of the University of Bern, Switzerland, according to the guidelines of Cantonal Veterinary. All animal experiments were performed according to ethical principles and guidelines of Cantonal Veterinary Office Bern, Switzerland. Five Female BALB/c mice (8–12 weeks) were subcutaneously immunized with 40 µg CuMV<sub>TT</sub>-RBD<sub>wt</sub> at d0 and boosted at d28. Serum samples were collected at d14, d21, d28, d35, d42, and d49 after priming. All mice in experiments did not show body weight loss and survived until d49, when we euthanized the mice.

### 2.6. ELISA

Antibody responses in immunized mice were examined with ELISA. Shortly, half-well Corning 96-well plate was coated with RBDs (1 µg/mL) at 4 °C overnight. Then the plate was blocked at room temperature for 2 h with PBS-0.15% Casein. Afterwards, serum samples were added, and a 3-fold serial dilution from 1:40 was performed. After 1 h incubation at room temperature, goat anti-mouse IgG-HRP (Jackson ImmunoResearch, West Grove, PA, USA) was added and incubated for 1 h. Finally, the developing solution (TMB in citrate buffer) was added, and the stop solution (1 M H<sub>2</sub>SO<sub>4</sub>) was added 5 min later. The plate was read at OD<sub>450nm</sub>, and IgG titer was calculated as the serum dilution times that reach half the maximum OD value.

To determine RBD-specific IgA antibodies in serum samples, the same assays were performed with some adjustments. Serum samples were incubated with Protein G magnetic beads (Thermo Scientific, Waltham, MA, USA) for 10 min at room temperature to remove IgG antibodies. Instead of an anti-IgG antibody, goat anti-mouse IgA-HRP antibody (ICN Cappel, Costa Mesa, CA, USA) was used as a detecting antibody.

### 2.7. Avidity ELISA

To assess the quality of RBD-specific IgG antibodies induced by CuMV<sub>TT</sub>-RBD<sub>wt</sub>, two parallel plates were performed as described in Section 2.6. To distinguish high-avidity

binding IgG antibodies from low-avidity binding ones, one plate was washed 3 times for 5 min with 7 M urea and the other with PBS-0.05% Tween [20]. The amounts of high-avidity antibodies were displayed with titer as well.

### 2.8. Neutralization Assay

The ability of immunized serum samples to neutralize SARS-CoV-2 virus Wuhan, South Africa (SA), Delta, and Brazilian variants were tested by means of cytopathic effect (CPE) formation [19]. Firstly, serum samples were heat-inactivated at 56 °C for 30 min and then 2-fold diluted from 1:20 until 1:160. Then, 100 TCID<sub>50</sub> of Wuhan wild type (SARS-CoV-2/ABS/NL20), SA (Beta: SARS-CoV-2/ABSB/BL21), Delta (SARS-CoV-2/ABSD/NL21), and Brazilian variant virus were added to each diluted serum and incubated for 1 h at 37 °C. Subsequently, the mixture was added to a monolayer of Vero cells and incubated for 4 days at 37 °C. Finally, the wells were inspected for the presence of cytopathic effect (CPE). Titer was expressed as the highest dilution of the serum that fully inhibits the formation of 100% CPE.


### 2.9. Statistical Analysis

Statistical analysis was performed using GraphPad Prism 7.0d. Unpaired Student's *t*-tests were used for IgG titers in ELISA, differences between plates with and without urea wash in avidity ELISA assays and neutralization titers. Statistical significance was indicated as *p* values: ≤0.05 (\*), ≤0.01 (\*\*), ≤0.001 (\*\*\*), ≤0.0001 (\*\*\*\*).

## 3. Results

### 3.1. Displaying RBD<sub>wt</sub> on CuMV<sub>TT</sub> VLP Surfaces

The production of the CuMV<sub>TT</sub>-RBD<sub>wt</sub> vaccine has been described previously [19]. In brief, we chemically coupled RBD<sub>wt</sub> protein expressed in eukaryotic HEK293 cells to CuMV<sub>TT</sub> VLPs. Figure 1A illustrates the principles of covalent reactions, which links the RBD<sub>wt</sub> internal cysteine to a lysine on the surface of the CuMV<sub>TT</sub> subunit via the heterobifunctional cross-linker SMPH. Efficient conjugation was confirmed by SDS-PAGE analysis, where a single VLP subunit can be distinguished from subunits coupled to RBD<sub>wt</sub>. In Figure 1B, the CuMV<sub>TT</sub>-RBD<sub>wt</sub> conjugation band is marked with a star. Because CuMV<sub>TT</sub> VLPs are produced in *E. coli*, they spontaneously package prokaryotic ssRNA to stabilize the capsid structure. As shown in agarose gel stained for RNA (Figure 1C), CuMV<sub>TT</sub>-RBD<sub>wt</sub>, as well as unmodified CuMV<sub>TT</sub> packaged ssRNA (left panel). The same gel stained for protein showed a band at the corresponding positions (right panels, Coomassie staining), indicating the presence of intact VLPs. Furthermore, the shape of CuMV<sub>TT</sub>-RBD<sub>wt</sub> was examined by transmission electron microscopy (Figure 1D), which demonstrated that CuMV<sub>TT</sub>-RBD<sub>wt</sub> remained as intact viral particles. These results demonstrated that the CuMV<sub>TT</sub>-RBD<sub>wt</sub> vaccine kept the properties of parent CuMV<sub>TT</sub> VLPs that incorporated RNA and preserved a spherical shape.




**Figure 1.** Generation and characterization of CuMV<sub>TT</sub>-RBD<sub>wt</sub>. **(A)** Scheme of covalent reactions between CuMV<sub>TT</sub>, RBD<sub>wt</sub> and SMPH. **(B)** SDS-PAGE gel analysis of CuMV<sub>TT</sub>-RBD<sub>wt</sub>. The coupled CuMV<sub>TT</sub>-RBD<sub>wt</sub> band (56.3kD) was marked with a star. **(C)** Examination of RNA contents inside CuMV<sub>TT</sub>-RBD<sub>wt</sub> comparing with CuMV<sub>TT</sub> VLP (left); the same agarose gel was stained with Coomassie, illustrating the protein bands located at the same position as RNA bands (right). **(D)** Transmission electron microscope image of CuMV<sub>TT</sub>-RBD<sub>wt</sub>, which demonstrates sphere viral shape.

### 3.2. CuMV<sub>TT</sub>-RBD<sub>wt</sub> Induces Strong Cross-Reactive IgG Responses

The immunogenicity of CuMV<sub>TT</sub>-RBD<sub>wt</sub> has been illustrated in previous work for wt RBD [19]. Here we assessed whether the antibodies are reactive to the newly emerged SARS-CoV-2 variants of concern (VOCs), which showed increased transmissibility, for instance, B.1.1.7, B.1.351, P.1 and B.1.617.1 variant. Of note, mutations in RBD protein, for example K417N and E484K, present in B.1.351 and P.1 variants reduce recognition by convalescent sera, while N501Y in B.1.1.7, B.1.351, and P.1 variants, L452R and E484Q in B.1.617.1 variant, increased the affinity to ACE2 receptor thereby causing reduced neutralization by affinity-escape [21,22] (Table 1). To this end, we produced recombinant RBD proteins containing the above mutations, namely RBD<sub>417</sub>, RBD<sub>484</sub>, RBD<sub>501</sub>, RBD<sub>trip</sub>, which includes three K417N, E484K, and N501Y mutations, and RBD<sub>dm</sub> containing L452R and E484Q mutation (shown

as Figure S1). Mice were immunized with CuMV<sub>TT</sub>-RBD<sub>wt</sub> at d0 and boosted at d28, and serum samples were collected weekly until d49, as illustrated in Figure 2A. ELISA results showed that antibodies induced by CuMV<sub>TT</sub>-RBD<sub>wt</sub> were able to recognize not only RBD<sub>wt</sub> but also all other mutated RBDs (Figure 2B–G). Overall, IgG antibody titers against all RBDs increased with time, especially after the booster injection.




**Figure 2.** Assessment of immunogenicity of CuMV<sub>TT</sub>-RBD<sub>wt</sub> in mice to RBDs of VOCs. (A) BALB/c mice were immunized with 40 µg CuMV<sub>TT</sub>-RBD<sub>wt</sub> at day 0 and boosted at day 28. Serum samples were collected weekly until d49. (B–G) IgG titers of d14 (B), d21 (C), d28 (D), d35 (E), d42 (F), d49 (G) against RBD<sub>wt</sub>, K417N mutation RBD<sub>417</sub>, E484K mutation RBD<sub>484</sub>, N501Y mutation RBD<sub>501</sub>, K417N, E484K, and N501Y mutation RBD<sub>trip</sub>, and L452R, E484Q mutation RBD<sub>dm</sub>. Statistical significance was analyzed using unpaired t-test, *p* values: ≤0.05 (\*), ≤0.01 (\*\*), ≤0.001 (\*\*\*), ≤0.0001 (\*\*\*\*).

IgG titers against RBD<sub>wt</sub> were superior to some of the RBD mutants after the first injection. After the second injection, differences, however, levelled out. Interestingly, as observed with convalescent sera and sera from immunized individuals (mRNA) [6], IgG titers against RBD<sub>484</sub> and RBD<sub>trip</sub> were significantly reduced after a single injection. In contrast, the titers against RBD<sub>417</sub>, RBD<sub>501</sub>, and RBD<sub>dm</sub> were only slightly lower, again reflecting what has been observed with convalescent sera and sera from immunized individuals (Figure 2B). In addition, the difference between IgG titers against RBD<sub>wt</sub>, RBD<sub>trip</sub>, and RBD<sub>dm</sub> were significant before the booster (Figure 2C,D). These results suggest that the CuMV<sub>TT</sub>-RBD<sub>wt</sub> vaccine was able to induce IgG antibodies that cross-react with VOCs, in particular after boosting; the ability to recognize RBD<sub>484</sub>, RBD<sub>trip</sub>, and RBD<sub>dm</sub> was the lowest, mirroring experience in humans with natural infection and mRNA immunization.

The differences between titers against RBD<sub>wt</sub> and RBD mutants became, however, much less pronounced, and all IgG titers were elevated to similar levels after the booster, albeit titers against RBD<sub>wt</sub> stayed highest (Figure 2E–G). Thus, cross-reactive IgG antibodies reached similar levels after the booster, indicating the booster vaccination unified the IgG responses.

### 3.3. CuMV<sub>TT</sub>-RBD<sub>wt</sub> Induces Strong Cross-Reactive IgA Responses

The ability of CuMV<sub>TT</sub>-RBD<sub>wt</sub> to induce cross-reactive IgA antibodies was assessed next. We have shown previously that RNA packaged in VLPs may drive systemic IgA responses [23], and IgA is well known to serve as a noninflammatory isotype that protects mucosal surfaces against infection. To this end, sera from immunized mice were tested for the presence of IgA antibodies specific to the various RBDs on d14 and d49 after immunization. As shown in Figure 3, IgA responses remained low after the first injection but strongly increased after the booster and reached high levels by day 49. As seen for the IgG responses, the IgA responses were highly cross-reactive, with mutation E484K being least recognized.




**Figure 3.** IgA antibody responses against all RBDs before boost (d14, (A)) and after boost (d49, (B)) of mice immunized with CuMV<sub>TT</sub>-RBD<sub>wt</sub>.

### 3.4. CuMV<sub>TT</sub>-RBD<sub>wt</sub> Induces IgG Antibodies Recognizing VOCs with High Avidity

To assess the avidity of the induced antibodies, we performed a modified immunoassay using 7M urea to detach low avidity antibodies. More specifically, we compared the avidity of the antibodies against the various RBDs in sera collected from day 14 and day 49. As expected, the avidity of antibodies on day 14 was relatively low for all RBDs, indicated by the strongly reduced ELISA signals in the plates washed with 7M urea (Figure 4A, red symbols). In contrast, avidity was strongly increased on day 49 after the boost. Remarkably,


the observed avidity was similar on all RBDs of VOCs and almost identical to avidities measured against wt RBD (Figure 4B).



**Figure 4.** Avidity ELISA of CuMV<sub>TT</sub>-RBD<sub>wt</sub> immunized mice sera to all RBDs at d14 (A) and d49 (B). IgG titers with (red symbols) and without (black symbols) 7M urea wash were displayed. Statistical significance was analyzed using unpaired t-test, *p* values: ≤0.05 (\*), ≤0.01 (\*\*), ≤0.001 (\*\*\*), ≤0.0001 (\*\*\*\*).

### 3.5. CuMV<sub>TT</sub>-RBD<sub>wt</sub> Induces IgG Antibodies Broadly Cross-Neutralizing VOCs

To determine the ability of the induced antibodies to neutralize VOCs, we have assessed the reduction of cytopathic effect (CPE) using 100TCID<sub>50</sub> of wild type and SARS-CoV-2 variants. Titers are expressed as the highest dilution that inhibits 100% formation of CPE. Interestingly, the d49 sera neutralized Wuhan (wt) as well as the Beta and Delta mutant at high titers and to the same extent. Only the Gamma variant was reduced to some degree (Figure 5). The reduced neutralization of the Gamma variant may be due to subtle differences in RBD (Table 1) or inherent differences between the viruses contributing to in vitro neutralization. Hence, these data demonstrate the ability of wt RBD displayed on CuMV<sub>TT</sub> to induce highly cross-reactive and cross-neutralizing antibodies, indicating that yearly generation of adapted vaccine generations as known for flu may not be necessary.



**Figure 5.** Titers of day 49 sera after immunization neutralizing Wuhan, Beta (South Africa), Delta (Indian) and Gamma (Brazilian) SARS-CoV-2 strains. Neutralization titers were determined as the highest dilution to inhibit 100% CPE formation. Statistical significance was analyzed using unpaired t-test, *p* values: ≤0.001 (\*\*\*)



#### 4. Discussion

The recently emerging VOCs raised the question of whether the currently available and developed vaccines may require yearly adaptation, as is known from the influenza virus [24]. This may not be the case for SARS-CoV-2 due to several reasons. (1) While both SARS-CoV-2 and influenza virus are RNA viruses, SARS-CoV-2 has a much more stable genome due to the presence of a proof-reading system [25]. (2) SARS-CoV-2 has a highly defined receptor, namely ACE2 and the binding is based on protein–protein interaction; indeed, the receptor-binding motif which is directly responsible for interaction with ACE2 shows no glycosylation or other post-translational modifications [26]; altered post-translational modifications are therefore not likely to interfere with this protein–protein interaction. In contrast, the influenza virus binds to variable carbohydrate structures via hemagglutinin and therefore has much more room for modifications [27,28]. (3) Consistent with (2), the independently emerged VOCs share a lot of common mutations, with position E484 or N417 or K501 being very frequently mutated. This also demonstrates that the virus has a limited operating range in terms of mutations. Nevertheless, the recently emerged Omicron VOC shows a larger number of mutations, and it will be interesting to reveal how this variant behaves in terms of neutralization. (4) The virus recently jumped from animals to humans, and it is therefore likely that these mutations observed now are part of the process of “human adaptation”. This theory is supported by the finding that the mutation within RBD, which determines the binding affinity of RBD to ACE2 and replication in human lung cells, is a key driver of SARS-CoV-2 to human adaptation [29]. (5) Established RNA viruses, such as Polio or Dengue virus, exist in three or four serotypes, respectively and show no evidence of further mutations to escape immunity. Indeed, poliovirus has been held at bay for decades using the same vaccine [30]. (6) Finally, we show here that a vaccine based on wt RBD displayed on CuMV<sub>TT</sub> is able to induce strongly and broadly cross-protective antibodies recognizing all VOCs efficiently. Taking points 1–6 into account, it will likely not be necessary to generate yearly versions of a SARS-CoV-2 vaccine. In addition to vaccine optimization, the world should therefore focus on broadening vaccine accessibility rather than vaccine specificity.

#### 5. Conclusions

Here, we present a vaccine candidate against Wuhan SARS-CoV-2 based on virus-like particle, CuMV<sub>TT</sub>-RBD<sub>wt</sub>, which can induce antibodies recognize not only RBD<sub>wt</sub>, but also RBDs of VOCs. These antibodies are able to neutralize VOCs *in vitro* as well. These results may be support the rationale for administration of wt vaccines globally to prevent the VOCs.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/vaccines10020307/s1>, Figure S1: SDS-PAGE gel of RBD<sub>wt</sub>, RBD<sub>417</sub>, RBD<sub>484</sub>, RBD<sub>501</sub>, RBD<sub>trip</sub> and RBD<sub>dm</sub>.

**Author Contributions:** X.C., M.V. and M.F.B. wrote and reviewed the manuscript; X.C and X.L. performed all the experiments; M.O.M. analyzed ELISA experiments; A.Z. provided CuMV<sub>TT</sub>; B.M. performed neutralization assay. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by Saiba AG and the Swiss National Science Foundation (SNF grants 310030\_185114).

**Institutional Review Board Statement:** The study was conducted according to the Cantonal Veterinary guidelines of Bern, Switzerland, and all experiments were performed in accordance with ethical principles and guidelines of the Cantonal Veterinary Office Bern, Switzerland (protocol code BE70/18 and date of approval 1 September 2018).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).

**Conflicts of Interest:** M.F.B. declares to be involved in several companies developing vaccines for allergic diseases. The other authors declare no further conflict of interests.

## References

1. Tang, J.W.; Tambyah, P.A.; Hui, D.S. Emergence of a new SARS-CoV-2 variant in the UK. *J. Infect.* **2021**, *82*, e27–e28. [[CrossRef](#)] [[PubMed](#)]
2. Tang, J.W.; Toovey, O.T.R.; Harvey, K.N.; Hui, D.D.S. Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK. *J. Infect.* **2021**, *82*, e8–e10. [[CrossRef](#)]
3. Priesemann, V.; Balling, R.; Brinkmann, M.M.; Ciesek, S.; Czypionka, T.; Eckerle, I.; Giordano, G.; Hanson, C.; Hel, Z.; Hotulainen, P.; et al. An action plan for pan-European defence against new SARS-CoV-2 variants. *Lancet* **2021**, *397*, 469–470. [[CrossRef](#)]
4. Jogalekar, M.P.; Veerabathini, A.; Gangadaran, P. SARS-CoV-2 variants: A double-edged sword? *Exp. Biol. Med.* **2021**, *246*, 1721–1726. [[CrossRef](#)] [[PubMed](#)]
5. Boehm, E.; Kronig, I.; Neher, R.A.; Eckerle, I.; Vetter, P.; Kaiser, L. Novel SARS-CoV-2 variants: The pandemics within the pandemic. *Clin. Microbiol. Infect.* **2021**, *27*, 1109–1117. [[CrossRef](#)] [[PubMed](#)]
6. Chang, X.; Augusto, G.S.; Liu, X.; Kündig, T.M.; Vogel, M.; Mohsen, M.O.; Bachmann, M.F. BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced. *Allergy Eur. J. Allergy Clin. Immunol.* **2021**, *76*, 2895–2998. [[CrossRef](#)] [[PubMed](#)]
7. Jangra, S.; Ye, C.; Rathnasinghe, R.; Stadlbauer, D.; Krammer, F.; Simon, V.; Martinez-Sobrido, L.; García-Sastre, A.; Schotsaert, M.; Alshammary, H.; et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. *Lancet Microbe* **2021**, *2*, e283–e284. [[CrossRef](#)]
8. Jangra, S.; Ye, C.; Rathnasinghe, R.; Stadlbauer, D.; Krammer, F.; Simon, V.; Martinez-Sobrido, L.; García-Sastre, A.; Schotsaert, M.; PVI Study Group. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. *medRxiv* **2021**. [[CrossRef](#)]
9. Augusto, G.; Mohsen, M.O.; Zinkhan, S.; Liu, X.; Vogel, M.; Bachmann, M.F. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. *Allergy Eur. J. Allergy Clin. Immunol.* **2022**, *77*, 111–117. [[CrossRef](#)]
10. Vogel, M.; Augusto, G.; Chang, X.; Liu, X.; Speiser, D.; Mohsen, M.O.; Bachmann, M.F. Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor-binding domain mutations: Receptor affinity versus neutralization of receptor interaction. *Allergy Eur. J. Allergy Clin. Immunol.* **2022**, *77*, 143–149. [[CrossRef](#)]
11. Cascella, M.; Rajnik, M.; Cuomo, A.; Dulebohn, S.C.; Di Napoli, R. *Features, Evaluation, and Treatment of Coronavirus*; StatPearls: Treasure Island, FL, USA, 2022.
12. Mohsen, M.O.; Balke, I.; Zinkhan, S.; Zeltina, V.; Liu, X.; Chang, X.; Krenger, P.S.; Plattner, K.; Gharailoo, Z.; Vogt, A.C.S.; et al. A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2. *Allergy Eur. J. Allergy Clin. Immunol.* **2022**, *77*, 243–257. [[CrossRef](#)] [[PubMed](#)]
13. Choi, A.; Koch, M.; Wu, K.; Chu, L.; Ma, L.Z.; Hill, A.; Nunna, N.; Huang, W.; Oestreicher, J.; Colpitts, T.; et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: An interim analysis. *Nat. Med.* **2021**, *27*, 2025–2031. [[CrossRef](#)] [[PubMed](#)]
14. Reece, J.C.; Geysen, H.M.; Rodda, S.J. Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. *J. Immunol.* **1993**, *151*, 6175–6184. [[PubMed](#)]
15. Zeltins, A.; West, J.; Zabel, F.; El Turabi, A.; Balke, I.; Haas, S.; Maudrich, M.; Storni, F.; Engeroff, P.; Jennings, G.T.; et al. Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy. *npj Vaccines* **2017**, *2*, 30. [[CrossRef](#)]
16. Gomes, A.C.; Roesti, E.S.; El-Turabi, A.; Bachmann, M.F. Type of RNA packed in VLPs impacts IgG class switching—implications for an influenza vaccine design. *Vaccines* **2019**, *7*, 47. [[CrossRef](#)]
17. Storni, F.; Zeltins, A.; Balke, I.; Heath, M.D.; Kramer, M.F.; Skinner, M.A.; Zha, L.; Roesti, E.; Engeroff, P.; Muri, L.; et al. Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens. *J. Allergy Clin. Immunol.* **2020**, *145*, 1240–1253.e3. [[CrossRef](#)]
18. Mohsen, M.O.; Rothen, D.; Balke, I.; Martina, B.; Zeltina, V.; Inchakalody, V.; Gharailoo, Z.; Nasrallah, G.; Dermime, S.; Tars, K.; et al. Neutralization of MERS coronavirus through a scalable nanoparticle vaccine. *npj Vaccines* **2021**, *6*, 107. [[CrossRef](#)]
19. Zha, L.; Chang, X.; Zhao, H.; Mohsen, M.O.; Hong, L.; Zhou, Y.; Chen, H.; Liu, X.; Zhang, J.; Li, D.; et al. Development of a vaccine against sars-cov-2 based on the receptor-binding domain displayed on virus-like particles. *Vaccines* **2021**, *9*, 395. [[CrossRef](#)]
20. Chang, X.; Zha, L.; Wallimann, A.; Mohsen, M.O.; Krenger, P.; Liu, X.; Vogel, M.; Bachmann, M.F. Low-affinity but high-avidity interactions may offer an explanation for IgE-mediated allergen-cross-reactivity. *Allergy* **2021**, *76*, 2565–2574. [[CrossRef](#)]
21. Gidari, A.; Sabbatini, S.; Bastianelli, S.; Pierucci, S.; Busti, C.; Monari, C.; Luciani Pasqua, B.; Dragoni, F.; Schiaroli, E.; Zazzi, M.; et al. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. *J. Infect.* **2021**, *83*, 467–472. [[CrossRef](#)]
22. Edara, V.V.; Norwood, C.; Floyd, K.; Lai, L.; Davis-Gardner, M.E.; Hudson, W.H.; Mantus, G.; Nyhoff, L.E.; Adelman, M.W.; Fineman, R.; et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. *Cell Host Microbe* **2021**, *29*, 516–521.e3. [[CrossRef](#)] [[PubMed](#)]

23. Bessa, J.; Jegerlehner, A.; Hinton, H.J.; Pumpens, P.; Saudan, P.; Schneider, P.; Bachmann, M.F. Alveolar Macrophages and Lung Dendritic Cells Sense RNA and Drive Mucosal IgA Responses. *J. Immunol.* **2009**, *183*, 3788–3799. [[CrossRef](#)] [[PubMed](#)]
24. Centers for Disease Control and Prevention. Influenza (Flu), About Flu. Available online: <https://www.cdc.gov/flu/about/index.html> (accessed on 21 January 2022).
25. Robson, F.; Khan, K.S.; Le, T.K.; Paris, C.; Demirbag, S.; Barfuss, P.; Rocchi, P.; Ng, W.L. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. *Mol. Cell* **2020**, *79*, 710–727. [[CrossRef](#)] [[PubMed](#)]
26. Wan, Y.; Shang, J.; Graham, R.; Baric, R.S.; Li, F. Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J. Virol.* **2020**, *94*, e00127-20. [[CrossRef](#)]
27. Luo, M. Influenza Virus Entry. In *Viral Molecular Machines*; Rossmann, M.G., Rao, V.B., Eds.; Springer: Boston, MA, USA, 2012; pp. 201–221. ISBN 978-1-4614-0980-9.
28. Skehel, J.J.; Wiley, D.C. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. *Annu. Rev. Biochem.* **2000**, *69*, 531–569. [[CrossRef](#)]
29. Kang, L.; He, G.; Sharp, A.K.; Wang, X.; Brown, A.M.; Michalak, P.; Weger-Lucarelli, J. A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation. *Cell* **2021**, *184*, 4392–4400.e4. [[CrossRef](#)]
30. Duintjer Tebbens, R.J.; Thompson, K.M. Poliovirus vaccination during the endgame: Insights from integrated modeling. *Expert Rev. Vaccines* **2017**, *16*, 577–586. [[CrossRef](#)]